GeroScience: Scientists identify new mechanisms of action for special drugs that fight Alzheimer's disease!

JANUARY 4, 2021 // -- In a recent study published in the international journal GeroScience, scientists from the University of Barcelona and other institutions identified a mechanism for the role of a potential compound against Alzheimer's disease in mice.
This new drug belongs to a family of molecules that, when combined with the Mide I2 subject, promotes a decrease in neuro-inflammatory levels, improvements in the body's cognitive function, and improvements in other markers of disease progression, which are most common in people with dementia.
Photo Source: Pixabay/CC0 Public Domain, a new compound with high affinity and selectivity to Midean I2 subjects, was designed and synthesized by researcher Carmen Escolano and is present in multiple organs and involved in a variety of body physiology processes, including analgesics, inflammation, and neurological disorders.
, it is also associated with the progression of neurodegeneration and appears to increase in the brains of Alzheimer's patients.
In previous studies, researchers have revealed the positive effects of these compounds on the evolution and progression of Alzheimer's disease, and based on previous research, the researchers aim to determine the mechanisms and parameters that change when drugs are used in animal models, especially in aging-related neurodegenerative mice, which are thought to be associated with the onset of late-onset Alzheimer's disease, meaning that symptoms of the disease begin at age 65. In the
study, researchers analyzed different biomarkers in the course of disease progression, as well as short- and long-term behavioral and memory test results in mice, to study the effects of therapy on mouse body behavior and memory, and found that when mice received the new drug, their body symptoms improved significantly compared to the control group.
The new molecule improves cognitive function in mice and reduces their anxiety symptoms, and the researchers have also confirmed at the molecular level that treatment based on this molecule may reduce typical neuroinstatic and oxidative stress in alzheimer's patients, while also reducing levels of pathological markers such as tau protein or β amyloid. the
-related findings may help researchers analyze the mechanism of effect of the new compound, while also providing evidence that molecular changes that occur after the treatment may be related to calcineurin pathways, which are responsible for the production of inflammatory mediated factors such as cytokines and the reduction of neuroplasticity.
the researchers say the findings may open up new possibilities for studies of the families of mitropod I2 mediators, as the results of cognitive improvements in neurodegenerative animal models depend on the mechanisms by which they work.
() Original source: Foteini Vasilopoulou et al, I2 imidazoline receptor modulation protects aged SAMP8 mice againstst the cognitive decline by suppressing the calcineurin pathway, GeroScience (2020). DOI:10.1007/s11357-020-00281-2。